Navidea biopharmaceuticals announces third-party asset valuation of tc99m tilmanocept for indications in rheumatoid arthritis

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the results of a third-party asset valuation of its rheumatoid arthritis (“ra”) diagnostic product candidate. the company engaged the independent third-party valuation firm, lifesci partners (lifesci advisors, llc), to perform a u.s.-focused market research valuation o
NAVB Ratings Summary
NAVB Quant Ranking